RAG Gene Modulation for CNS Axon Regeneration and Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Adult CNS axons do not regenerate spontaneously after degeneration, leading to irreversible neuronal function deficits, and current treatments for glaucoma only reduce intraocular pressure without preventing neurodegeneration.
Innovation Solution
Enhance the activity of axon regeneration-associated genes (RAGs) such as ANXA2, tPA, GSN, VIM, MPP1, ILK, ECM1, CALM1, and ACAA2 using gene therapy vectors like AAV to promote axon regeneration and neuroprotection in retinal ganglion cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If Pten deletion is used to promote axon regeneration, then axon regeneration activity is enhanced, but deleterious side effects such as metabolic diseases, tumor formation, and cognitive impairment occur
Solution Approach 1:
The patent extracts and isolates the specific downstream effector molecules (GSK3β, mTORC1) that mediate axon regeneration from the complex Pten signaling pathway. By targeting these specific molecules rather than deleting Pten globally, the invention achieves axon regeneration promotion while avoiding the broad deleterious side effects of Pten deletion including metabolic diseases, tumor formation, and cognitive impairment.
Solution Approach 2:
The patent applies local quality by using cell-type-specific (RGC-specific) and stage-specific regulation of the downstream effectors. The therapeutic approach targets GSK3β and mTORC1 activity specifically in retinal ganglion cells during the regeneration phase, rather than systemically, thereby achieving localized regenerative effects without widespread harmful consequences.
2Stress or pressure
If current glaucoma treatments reduce intraocular pressure, then IOP is lowered, but neurodegeneration progression is not prevented
Solution Approach 1:
The patent introduces downstream effector molecules (GSK3β, mTORC1) as intermediary therapeutic targets that mediate between IOP reduction and neurodegeneration prevention. By modulating these intermediary signaling molecules, the invention creates a therapeutic bridge that translates IOP control into active neuroprotection and axon regeneration, overcoming the limitation of current IOP-lowering treatments.
Solution Approach 2:
The patent replaces the purely mechanical/physical approach of IOP reduction with a biochemical signaling approach. Instead of relying solely on mechanical pressure reduction, the invention uses molecular signaling modulation (GSK3β inhibition, mTORC1 activation) to actively promote neuronal survival and regeneration, substituting mechanical control with biochemical regulation.
3Quantity of substance
If bulk RNA-seq is performed on Pten KO RGCs without differentiation, then gene expression is analyzed, but regenerating RGCs cannot be distinguished from surviving non-regenerating RGCs
Solution Approach 1:
The patent segments the homogeneous Pten KO RGC population into distinct functional subgroups: regenerating RGCs and surviving non-regenerating RGCs. This segmentation is achieved through specific markers and functional assays that differentiate cells based on their regeneration status, enabling precise analysis of gene expression profiles specific to regenerating cells rather than the mixed population.
Solution Approach 2:
Instead of trying to identify regenerating RGCs within the bulk Pten KO population, the patent inverts the approach by first identifying and isolating regenerating RGCs using specific markers (such as growth cone markers, regeneration-associated gene expression), then performing RNA-seq on this purified subset. This inversion enables precise molecular characterization of the regenerating subset.
Data Source
AI summary
Composition and methods are provided for the treatment of a mammalian subject for axonopathies by increasing activity of axon regeneration-associated gene (RAG) as identified herein, which include without limitation ANXA2, TPA, GSN, VIM, MPP1, ILK, ECM1, CALM1, AND ACAA2. These genes are shown to significantly promote axon regeneration, dramatically protects retinal ganglion cells and optic nerves, and preserve visual function in a clinically relevant model of glaucoma. A therapeutic entity may comprise, for example, a RAG protein, a gene therapy vector comprising a RAG coding sequence, a small molecule that enhances RAG activity, and the like.